Revolution Medicines 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
132 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lerociclib (G1T38) / Walvax, Pharmacosmos
LEONARDA-1, NCT05054751: GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Completed
3
275
RoW
GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant
Genor Biopharma Co., Ltd.
Locally Advanced or Metastatic Breast Cancer
12/22
03/24
ENGOT-EN17, NCT05712941: Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

Withdrawn
3
320
NA
Lerociclib, Letrozole 2.5mg, Placebo
EQRx International, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Endometrial Carcinoma
03/24
03/25
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Recruiting
3
350
RoW
GB491 combined with Letrozole, Placebo combined with Letrozole
Genor Biopharma Co., Ltd.
Breast Cancer
01/26
01/27
NCT05085002 / 2021-005238-40: A Study of Lerociclib in Participants With Advanced Breast Cancer

Terminated
2
100
Europe, US, RoW
Lerociclib + Letrozole or Fulvestrant
EQRx, Inc.
Advanced Breast Cancer
11/23
11/23
NCT02983071 / 2016-001485-29: G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Active, not recruiting
1/2
102
Europe, RoW
G1T38, lerociclib, Fulvestrant, Faslodex
G1 Therapeutics, Inc.
Carcinoma, Ductal, Breast, Breast Cancer, Breast Neoplasm
06/23
10/23
NCT05860582: A Study of [14C]GB491 in Male Healthy Subjects

Completed
1
6
RoW
[14C]GB491
Genor Biopharma Co., Ltd.
Breast Cancer, Nonsmall Cell Lung Cancer
11/22
11/22
NCT05337657: A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Recruiting
1
10
RoW
GB491+Letrozole
Genor Biopharma Co., Ltd.
Advanced Breast Cancer
12/23
02/24
vociprotafib (RMC-4630) / Revolution Medicines
2021-003254-23: Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies

Not yet recruiting
2
46
Europe
RMC-4630 - 20 mg, LUMYKRAS, RMC-4630 - 100 mg, RMC-4630, Sotorasib, Capsule, Tablet, -, Sotorasib, RMC-4630
Revolution Medicines, Inc., Revolution Medicines
Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies, Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies, Diseases [C] - Cancer [C04]
 
 
RMC-4630-03, NCT05054725 / 2021-003254-23: Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Completed
2
47
Europe, Canada, US, RoW
RMC-4630, SAR442720, Sotorasib, AMG 510, Lumakras
Revolution Medicines, Inc., Sanofi, Amgen
Non-Small Cell Lung Cancer
07/24
08/24
NCT04418661: Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

Terminated
1/2
65
Europe, US, RoW
Vociprotafib, SAR442720, RMC-4630, Pembrolizumab, Adagrasib
Sanofi, Revolution Medicines, Inc., Mirati Therapeutics Inc.
Metastatic Neoplasm
04/24
04/24
NCT03634982: Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Active, not recruiting
1
133
US
RMC-4630
Revolution Medicines, Inc., Sanofi
Solid Tumors
03/23
05/23
SHERPA, NCT04916236: Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

Terminated
1
24
Europe
RMC-4630, SAR442720, LY3214996
The Netherlands Cancer Institute, Lustgarten Foundation
Pancreatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, KRAS Mutation-Related Tumors
07/24
07/24
CodeBreak101, NCT04185883 / 2020-004721-23: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen, Amgen Inc, Amgen Inc.
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
06/26
12/27
Ameile (aumolertinib) / Jiangsu Hansoh Pharma
ChiCTR2000040853: A prospective, multicenter, real world study: Almonertinib mesilate tablets for EGFR Positive locally advanced or metastatic Non-Small Cell Lung Cancer

Recruiting
4
300
 
Non-intervention study
JiangSu Cancer Hospital; JiangSu Cancer Hospital, Lian Yun Gang Shi Hui Lan Public Foundation
Lung Cancer
 
 
ChiCTR2200055992: Mechanism of resistance to second-line Aumolertinib and exploring combined treatment after resistance

Not yet recruiting
4
50
 
Aumolertinib
The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, Huilan Public Welfare Foundation
Lung cancer
 
 
ChiCTR2000035591: Multi-Center Clinical Study on the Efficacy and Safety of Almonertinib Combined with Bevacizumab and Pemetrexed in the First-Line Treatment of EGFR-Mutant Lung Adenocarcinoma Patients with Brain Metastases

Not yet recruiting
4
200
 
Almonertinib Combined with Bevacizumab and Pemetrexed
Shandong Cancer Hospital Affiliated to Shandong University; Shandong Cancer Hospital Affiliated to Shandong University, This work was partly supported by Lianyungang Huilan Public Welfare Foundation, and the rest is self-funded
Lung Adenocarcinoma
 
 
ChiCTR2100046251: Evaluate the Safety and Efficacy of Almonertinib in the Treatment of Advanced NSCLC Patients With EGFR-Sensitive Mutations Who Are Safety Intolerant After Osimertinib Treatment: a Prospective, Multi-Center, Single-Arm Clinical Trial

Recruiting
4
40
 
received 110 mg of Almonertinib orally once a day
Shanghai Chest Hospital; The Affiliated Tumor Hospital of Chongqing University, Sponsored by Jiangsu Hausen Pharmaceutical Group Co., Ltd.
Non-small-cell lung carcinoma
 
 
ChiCTR2200057150: A prospective, open, randomized, controlled, multicenter trial of postoperative adjuvant chemoradical radiotherapy followed by sequential maintenance therapy with ametinib versus postoperative adjuvant chemoradical radiotherapy in patients with stage N2-III NSCLC with EGFR mutations

Not yet recruiting
4
102
 
Aumolertinib after adjuvant chemotherapy/radiotherapy ;Adjuvant chemotherapy/radiotherapy
The People's Hospital of Guizhou Province; The People's Hospital of Guizhou Province, Huilan charity-Hansoh pharma
non-small cell lung cancer (NSCLC)
 
 
SELECT-2, NCT04401059: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study

Recruiting
4
744
RoW
Elemene plus first or third generation EGFR-TKIs, H10960114, H20010338, First or third generation EGFR-TKIs, Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc.
Tian Xie, LinkDoc Technology (Beijing) Co. Ltd.
Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma
09/25
03/26
ChiCTR2100042856: Clinical study of ametinib as neoadjuvant therapy in EGFR positive patients with stage IIB to IIIA non-small cell lung cancer

Recruiting
4
30
 
almonertinib
Huadong Hospital; Huadong Hospital, LIAN YUN GANG SHI HUI LAN PUBLIC FOUNDATION
Lung Cancer
 
 
ChiCTR2200063184: A multicenter, open-label, single-arm clinical study of Aumolertinib mesylate as postoperative adjuvant treatment for patients with EGFRm positive stage IB and pure solid stage IA2-3 invasive non-small cell lung cancer

Not yet recruiting
4
130
 
Aumolertinib as postoperative adjuvant therapy
The First Affiliated Hospital of Sun Yat-sen University ; The First Affiliated Hospital of Sun Yat-sen University, Huilan charity-Hansoh pharma
non-small cell lung cancer (NSCLC)
 
 
ChiCTR2200062887: A multicenter, open-label, single-arm clinical study of Aumolertinib mesylate as postoperative adjuvant treatment for patients with EGFRm positive stage IB and pure solid stage IA2-3 invasive Non-Small Cell Lung Cancer

Not yet recruiting
4
130
 
Aumolertinib as postoperative adjuvant therapy
The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University, Huilan charity-Hansoh pharma
Lung Cancer
 
 
CTR20201857: Phase III clinical study of ametinib mesylate or placebo combined with chemotherapy as perioperative treatment for non-small cell lung cancer

Not yet recruiting
3
350
China
Ameile (aumolertinib) - Jiangsu Hansoh Pharma, EQRx, Pemfexy (pemetrexed) - Eagle Pharma, cisplatin - Generic mfg., carboplatin - Generic mfg.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd./Shanghai Hansoh Biomedical Technology Co., Ltd.
Non-small cell lung cancer;Oncology
 
 
AENEAS, NCT03849768: A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Active, not recruiting
3
429
RoW
HS-10296, Investigational Product, Gefitinib, Comparator Product
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
01/21
06/23
ACROSS1, NCT04500704: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Not yet recruiting
3
166
RoW
Almonertinib, Ameile, Almonertinib plus carboplatin and pemetrexed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
12/21
10/23
ACROSS2, NCT04500717: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Not yet recruiting
3
460
RoW
Almonertinib, Aleime, Almonertinib plus carboplatin and pemetrexed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
10/22
10/23
APPROACH, NCT04841811: MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.

Recruiting
3
192
RoW
Almonertinib, ctDNA dynamic monitoring guided the Almonertinib treatment
Guangdong Association of Clinical Trials, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer
12/24
12/26
ACROSS 1, ChiCTR2000032354: Almonertinib Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Patients With EGFR Mutation Positive With Concomitant Non-EGFR Driver Gene Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Randomized, Control Phase III Study

Recruiting
3
166
 
Almonertinib 110mg PO once daily ;110mg PO once daily and 500 milligrams per square meter (mg/m2) Pemetrexed and AUC=5 Carboplatin taken intravenously (IV) once every 3 weeks concurrently with Almonertinib taken orally QD.
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, self-financing and partial sponsorship of Jiangsu Haosen Pharmaceutical Group Co., Ltd
NSCLC
 
 
ACROSS 2, ChiCTR2000032319: Almonertinib Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Patients With EGFR Mutation Positive With Concomitant Tumor Suppressor Gene Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Randomized, Control Phase III Study

Recruiting
3
460
 
Almonertinib, 110mg, P.O., once daily and 500 milligrams per square meter (mg/m2) Pemetrexed and AUC=5 Carboplatin taken intravenously (IV) once every 3 weeks concurrently with Almonertinib taken orally QD. ;Almonertinib, 110mg, P.O., once daily
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, self-financing and partial sponsorship of Jiangsu Haosen Pharmaceutical Group Co., Ltd.
NSCLC
 
 
TREBLE, NCT05493501: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Terminated
3
8
US
Aumolertinib monotherapy, EQ143, HS-10296, Osimertinib monotherapy, Tagrisso, Pemetrexed, Alimta, Cisplatin, Carboplatin, Paclitaxel, Taxol, Nab paclitaxel, Abraxane, Albumin-bound paclitaxel, Gemcitabine, Gemzar
EQRx International, Inc.
NSCLC
08/23
08/23
NCT04951648: A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Not yet recruiting
3
220
RoW
Almonertinib, HS-10296, chemotherapy
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
10/23
09/24
AENEAS2, NCT04923906: Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Active, not recruiting
3
624
RoW
Aumolertinib, HS-10296, Placebo Aumolertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
06/24
01/26
ATTACK, NCT04870190: Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Not yet recruiting
3
232
NA
Almonertinib, HS-10296, Osimertinib, Teresa, AZD9291
Shanghai Chest Hospital
NSCLC
06/24
06/24
ChiCTR2100047453: Efficacy and safety of almonertinib combined with apatinib versus almonertinib as a single agent in the first-line treatment of advanced NSCLC with EGFR-sensitive mutations: a multicenter, randomized, open, controlled phase iii clinical study

Recruiting
3
300
 
Almonertinib 110mg PO once daily plus apatinib 250mg PO once daily ;Almonertinib 110mg PO once daily
Chinese PLA General Hospital; Chinese PLA General Hospital, Self-raised and sponsored by Jiangsu Haosen Pharmaceutical Group Co., Ltd., and sponsored by Jiangsu Hengrui Pharmaceutical Co., Ltd.
NSCLC
 
 
POLESTAR, NCT04951635: A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Recruiting
3
150
RoW
Almonertinib, HS-10296, Placebo Almonertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
07/24
01/27
ADVANCE, ChiCTR2000040590: Almonertinib Plus Radiotherapy compared with Concurrent RadioChemotherapy in the treatment of unresectable EGFR-mutated stage III Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Randomized, Control Phase III Study

Not yet recruiting
3
254
 
Almonertinib 110mg PO once daily ;Cisplatin（75mg/m2），and 500 milligrams per square meter (mg/m2) Pemetrexed
Cancer Hospital Chinese Acadmey of Medical Sciences, Shenzhen Center; Shanghai chest hospital, self-financing and partial sponsorship of Jiangsu Haosen Pharmaceutical Group Co., Ltd
NSCLC
 
 
HS-10241-301, NCT06110663: A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Not yet recruiting
3
314
NA
HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
12/24
02/25
ARTS, NCT04687241: Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Active, not recruiting
3
192
RoW
Almonertinib, HS-10296, Placebo Almonertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
07/24
01/29
APEX, NCT04762459: Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

Enrolling by invitation
3
606
RoW
Almonertinib, Pemetrexed, Cisplatin
Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd., GeneCast Biotechnology Co., Ltd.
Non-small Cell Lung Carcinoma
05/26
05/29
NCT06043973: Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Recruiting
3
98
RoW
almonertinib, Anlotinib
Qianfoshan Hospital
Advanced Non-small Cell Lung Cancer
09/26
06/27
NCT05800223: Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Recruiting
3
300
RoW
Almonertinib, SBRT
Shanghai Cancer Hospital, China
Non-small Cell Lung Cancer Metastatic
12/27
12/28
NCT05768490: Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Recruiting
3
232
RoW
brain radiotherapy, Almonertinib
Sun Yat-sen University
Brain Metastases, Radiotherapy, EGFR Activating Mutation
12/28
12/29
HS-20117 301, NCT06417008: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Not yet recruiting
2/3
1080
NA
HS-20117, PM1080, Aumolertinib, Almonertinib Mesilate Tablets, HS-10296, Almonertinib
Hansoh BioMedical R&D Company
Non-Squamous Non-Small Cell Lung Cancer
06/26
06/30
NCT05994339: Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Not yet recruiting
2/3
40
NA
Almonertinib, Intensity-Modulated Radiation Therapy(IMRT)
Laibin People's Hospital
Lung Cancer Stage III
08/25
12/25
NCT04646824: Almonertinib With Chemotherapy in mEGFR NSCLC

Active, not recruiting
2
10
RoW
Almonertinib Pemetrexed/Cisplatin
Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer Metastatic
11/20
11/22
NCT04671303: To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

Completed
2
36
RoW
Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer
06/23
07/23
NCT04636593: A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Recruiting
2
43
RoW
Almonertinib, Thoracic Radiotherapy
First People's Hospital of Hangzhou, Hangzhou Cancer Hospital
Non Small Cell Lung Cancer, Stage III NSCLC, EGFR Activating Mutation
12/21
12/22
APPEAL, NCT04592666: Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer

Not yet recruiting
2
226
RoW
Almonertinib, Pemetrexed, Carboplatin
Fudan University
Lung Cancer, Non-small Cell, EGFR T790M, EGFR Gene Mutation
12/21
06/22
GASTO 1063, NCT04978753: the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Recruiting
2
54
RoW
Anlotinib, almonertinib
Li-kun Chen
Non-small Cell Lung Cancer, Brain Metastases
05/22
12/23
NCT04952168: Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Recruiting
2
26
RoW
Almonertinib
Yuan Chen
NSCLC, Stage III
06/22
06/23
NCT04423185: PLATFORM Study of Precision Medicine for Rare Tumors

Recruiting
2
770
RoW
Almonertinib 110 MG, HS-10296, AMEILE, Dacomitinib 45 MG, Vizimpro, Alectinib 150 MG, Alecensa, Crizotinib 250 MG, Xalkori, Pyrotinib 160/80 MG, SHR-1258, Imatinib 400 MG, Gleevec, Niraparib 200/300 MG, Niraparix, Palbociclib 125mg, Ibrance, Vemurafenib 240 MG, Zelboraf, Sintilimab 100MG, Tyvyt, Atezolizumab 1680 MG, TECENTRIQ
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rare Tumor
07/26
07/28
NCT04643847: A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Not yet recruiting
2
47
RoW
Almonertinib, HS-10296
First People's Hospital of Hangzhou
EGFR Positive Non-small Cell Lung Cancer, Brain Metastases
11/22
11/23
NCT03904823: A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

Recruiting
2
58
RoW
famitinib po, HS-10296 po
Jiangsu HengRui Medicine Co., Ltd.
EGFR-mutant Non-Small Cell Lung Cancer
12/22
12/22
PIKACHU, NCT04322890: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Recruiting
2
6000
RoW
Osimertinib, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc., Alectinib 150 MG, Lorlatinib, Alectinib, Brigatinib, Ceritinib etc., Crizotinib 250 MG, Entrectinib, Savolitinib, Crizotinib., Crizotinib, Chemotherapy, Pemetrexed, Cisplatin, Pralsetinib etc.
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation
12/26
12/27
LungMate-007, NCT04685070: Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Active, not recruiting
2
56
RoW
HS-10296 (Almonertinib)
Shanghai Pulmonary Hospital, Shanghai, China
Non-small Cell Lung Cancer Stage III
12/22
12/27
ChiCTR2200066768: Clinical observation of Aumolertinib in the treatment of residual ground glass nodules in patients with Ⅰ stage EGFR mutation positive after resection of lung cancer

Not yet recruiting
2
40
 
Aumolertinib
Tianjin medical university cancer institute&hospital; Tianjin medical university cancer institute&hospital, None
Lung Cancer
 
 
ANSWER, NCT04455594: Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

Not yet recruiting
2
168
RoW
Almonertinib, HS-10296, Erlotinib, Cisplatin, Carboplatin, Pemetrexed
The First Affiliated Hospital of Guangzhou Medical University
Non-Small Cell Lung Cancer Stage IIIA
01/23
10/25
MWA, NCT04755738: Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer

Not yet recruiting
2
234
RoW
Almonertinib plus microwave ablation, Microwave ablation
Qianfoshan Hospital, Shandong Provincial Hospital
Advanced Non Small Cell Lung Cancer
03/23
03/25
AUTUMN, NCT04553887: Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial

Not yet recruiting
2
53
RoW
Almonertinib
Tianjin Medical University Cancer Institute and Hospital
Non Small Cell Lung Cancer
05/23
05/23
ChiCTR2100049904: Clinical observation of continuous treatment with almonertinib after treatment with osimertinib in EGFR mutation positive advanced NSCLC patients with drug resistance

Not yet recruiting
2
30
 
Almonertinib 110 mg orally,once a day
Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University; Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Huilan charity-Hansoh pharma
Lung Cancer
 
 
APPEAR, NCT04785729: Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance

Recruiting
2
36
RoW
Almonertinib combine with Pyrrolitinib
Sun Yat-sen University
Safety
12/23
12/23
NCT04519983: Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

Recruiting
2
40
RoW
Aumolertinib Oral Tablet, Stereotactic Radiation Therapy
Shanghai Cancer Hospital, China
Lung Cancer Stage IV
12/23
12/23
NCT05754736: Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

Recruiting
2
50
RoW
Ametinib combined with bevacizumab, Third-generation TKI combined with antivascular targeting drug
The Second Affiliated Hospital of Shandong First Medical University
Non-small Cell Lung Cancer
12/23
12/25
NCT05662813: Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Recruiting
2
55
RoW
Almonertinib, HS-10296
West China Hospital
Non-small Cell Lung Cancer
12/23
06/25
ChiCTR2000039310: Platform Study of Genotyping Guided Precision Medicine for Rare Tumors in China

Recruiting
2
208
 
Almonertinib, 110mg, qd ;Dacomitinib, 450mg, qd ;Alectinib, 600mg, bid ;Crizotinib, 250mg, bid ;Zelboraf, 960mg, bid ;Niraparib,200-300mg,qd ;Pyrotinib, 400mg, qd ;Imatinib, 400mg, bid ;Palbociclib, 125mg,*21d, q28d ;Sintilimab, 200mg, q21d ;Atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d
National Cancer Center/National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital of Chinese Academy of Medical Sciences, self-raised
Rare Tumors
 
 
NCT04785742: Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

Enrolling by invitation
2
40
RoW
Almonertinib
Sun Yat-sen University
Safety of Almonertinib
12/23
12/23
ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma

Recruiting
2
13
RoW
Almonertinib, Investigational Product
Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Pulmonary Adenosquamous Carcinoma
12/23
06/25
ACTIVE, NCT04882345: Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Not yet recruiting
2
40
NA
Almonertinib, HS-10296
Shanghai Chest Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer, EGFR Gene Mutation
01/24
01/24
NCT06185400: RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Not yet recruiting
2
108
NA
Disitamab Vedotin, RC48, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib), pyrotinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, ERBB2 Gene Duplication, Disitamab Vedotin
07/25
12/26
NCT04905550: Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Recruiting
2
50
RoW
Almonertinib, The third generation of EGFR - TKI, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
Chongqing University Cancer Hospital
Non-Small Cell Lung Cancer (NSCLC)
03/24
08/24
ACHIEVE, NCT04808752: Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

Active, not recruiting
2
63
RoW
Almonertinib, Investigational Product
Zhejiang Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer
06/24
07/24
NEOVADE, NCT06300424: Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Recruiting
2
32
RoW
almonertinib, Carboplatin, Nab paclitaxel
Guangdong Provincial People's Hospital
Non Small Cell Lung Cancer, EGFR Gene Mutation
03/26
09/27
APPOINT, NCT04922138: Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns

Recruiting
2
104
RoW
Aumolertinib, HS-10296
Baohui Han, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer
04/24
10/25
NCT06463171: Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Not yet recruiting
2
60
RoW
Almonertinib, Lastet
Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Zhongshan Hospital, The First Affiliated Hospital of Xiamen University
Lung Cancer Non-small Cell Stage IV
06/26
06/26
NCT06452433: Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Not yet recruiting
2
91
NA
gumarontinib, SCC244, third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib), third-generation EGFR-TKI
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer
12/27
02/28
AERESA, NCT06227897: Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC ().

Withdrawn
2
85
RoW
Aumolertinib, almonertinib, HS-10296
Sun Yat-sen University
Lung Cancer
04/26
04/29
ANSWER, ChiCTR2000033677: Almonertinib vs. Erlotinib / Chemotherapy for Neo-Adjuvant Treatment of Stage IIIA-N2 EGFR-Mutated NSCLC: a Multicenter, Open-Label, Phase II Randomized Controlled Trial

Not yet recruiting
2
168
 
Almonertinib 110mg PO once daily ;Investigator-choice therapy: Erlotinib 150mg PO once daily or 500 milligrams per square meter (mg/m2) Pemetrexed and AUC=5 Carboplatin/75 milligrams per square meter (mg/m2) cisplatin taken intravenously (IV) once every 3 weeks
The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University, Self-financing and partial sponsorship of Jiangsu Haosen Pharmaceutical Group Co., Ltd.
NSCLC
 
 
ANOTHER, NCT06752408: Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Not yet recruiting
2
316
RoW
Aumolertinib, Osimertinib
Peking Union Medical College Hospital, Peking University People's Hospital, China-Japan Friendship Hospital
Non Small Cell Lung Cancer
01/27
01/28
NCT05810350: Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Recruiting
2
40
RoW
Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed
Three Gorges Hospital of Chongqing University
Non-small Cell Lung Cancer
12/24
12/24
NCT05778149: Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Not yet recruiting
2
47
NA
Aumolertinib,Anlotinib
Tianjin Medical University Cancer Institute and Hospital
Aumolertinib, Anlotinib, TP53, NSCLC, EGFR Activating Mutation
03/25
03/27
NCT06951464: Phase II Study of BL-B01D1 and Almonertinib for EGFR+ Stage II-IIIB NSCLC

Not yet recruiting
2
40
NA
BL-B01D1, Almonertinib
Sichuan University
Non-Small Cell Lung Cancer
05/27
03/29
NCT05534113: Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Not yet recruiting
2
38
NA
Almonertinib Envafolimab
The First Affiliated Hospital with Nanjing Medical University
Non-small Cell Lung Cancer
06/25
06/25
NCT05946460: Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Recruiting
2
22
RoW
Aumolertinib
The First Affiliated Hospital of Guangzhou Medical University
Lung Cancer
07/25
07/25
ChiCTR2300075120: Efficacy and Safety of Ametinib Combined With Bevacizumab in First-line Treatment of Non-oligometastatic Advanced NSCLC With EGFR-mutations.

Recruiting
2
100
 
Almonertinib plus bevacizumab
The Second Affiliated Hospital of Shandong First Medical University; The Second Affiliated Hospital of Shandong First Medical University, Self-funded
Lung cancer
 
 
ChiCTR2400083981: Phase II Clinical Study of Almonertinib in Combination with LASTET in the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer with EGFR Mutations

Not yet recruiting
2
60
 
Almonertinib in Combination with LASTET
shanghai pulmonary hospital; shanghai pulmonary hospital, Shanghai Pulmonary Hospital
Non-Small Cell Lung Cancer
 
 
ChiCTR2500095661: A Multicenter, Single-Arm, Phase II Study of High-Dose Almonertinib as First-Line Treatment for Patients with EGFR Exon 21 L858R-Mutated Advanced Lung Adenocarcinoma (LUAD)

Recruiting
2
122
 
Almonertinib 165mg, oral, once daily (QD)
The Affiliated Panyu Central Hospital of Guangzhou Medical University; The Affiliated Panyu Central Hospital of Guangzhou Medical University, Self-funded
EGFR Exon 21 L858R-Mutated Advanced Lung Adenocarcinoma
 
 
ChiCTR2300078018: Efficacy and safety of Almonertinib as postoperative adjuvant therapy for completely resected stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations

Not yet recruiting
2
50
 
Targeted Therapy Intervention
Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, HANSOH PHARMACY
completely resected IB-IIIA non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations (except for 20ins)
 
 
PURPOSE Trial, ChiCTR2100053021: Precise neoadjuvant therapy for locally advanced non-small cell lung cancer: a prospective, observational, umbrella trial

Not yet recruiting
2
156
 
Almonertinib ;Furmonertinib ;Osimertinib ;Ensartinib/Savolitinib/Pralsetinib/Pyrotinib ;Camrelizumab+chemotherapy ;Chemotherapy
Shanghai Chest Hospital; Shanghai Chest Hospital, Self-raised
Locally advanced non-small cell lung cancer
 
 
ChiCTR2500102344: A Phase II Study to Evaluate the Safety and Efficacy of Neoadjuvant Therapy with BL-B01D1 in Combination with Almonertinib Followed by Adjuvant Almonertinib in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIB Resectable Non-Small Cell Lung Cancer

Not yet recruiting
2
40
 
BL-B01D1 plus Almonertinib
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Self-selected topic (self-sponsored)
Stage II-IIIb non-small cell lung cancer with sensitive EGFR mutations
 
 
SHR-A2009-201, CTR20233099: An open-label, multicenter phase IB/II clinical study of the safety, tolerability and efficacy of SHR-A2009 for injection in combination with anti-tumor therapy in patients with advanced solid tumors

Recruiting
1b/2
270
China
SHR-A2009 - Jiangsu Hengrui Pharma, adebrelimab (SHR-1316) - Jiangsu Hengrui Pharma, Ameile (aumolertinib) - Jiangsu Hansoh Pharma
Shengdia Biopharmaceutical Co., Ltd
Advanced solid tumors
 
 
APOLLO, NCT02981108: A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

Active, not recruiting
1/2
364
US
HS-10296
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Nonsmall Cell Lung Cancer
01/19
03/23
ChiCTR2100049102: Aumolertinib combined with bevacizumab in the first-line treatment of advanced NSCLC patients with EGFR-sensitive mutations and malignant pleural effusion and/or malignant pericardial effusion: a phase I/II clinical study

Not yet recruiting
1/2
36
 
Aumolertinib 110 mg orally, once a day; bevacizumab 15 mg/kg intravenous drip (on the first day of each cycle), every 21 days as a cycle.
The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, Huilan Charity-Hansoh pharma
non-small cell lung cancer
 
 
NCT06474455: A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
156
RoW
SHR-9839 ；SHR-A2009, SHR-9839 ； SHR-A1921, SHR-9839 ； pemetrexed ；carboplatin, SHR-9839 ； Almonertinib
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
06/26
06/27
ChiCTR2200060886: A phase Ⅰ/Ⅱ study of Almonertinib with Bevacizumab in the first-line treatment of EGFR-mutant non-squamous non-small cell lung cancer patients with brain metastases

Not yet recruiting
1/2
94
 
NA
The Second Affiliated Hospital of Chongqing Medical University ; The Second Affiliated Hospital of Chongqing Medical University, self-financing
lung cancer
 
 
APEAK, NCT06947811: A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

Recruiting
1/2
71
RoW
Almonertinib, Palbociclib
Sun Yat-sen University
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
03/27
03/27
SHR-A2009-201, NCT06092268: A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
270
NA
SHR-A2009 for injection ； Almonertinib Mesilate Tablets, SHR-A2009 for injection；Adebrelimab Injection
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
12/25
12/25
SHR-1701-215, NCT05503888: Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Not yet recruiting
1/2
160
NA
Almonertinib combined with SHR-1701, Almonertinib
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Relapsed or Advanced Non-small Cell Lung Cancer
07/27
07/27
ChiCTR2500101627: A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations (APEAK)

Not yet recruiting
1/2
72
 
Almonertinib+Palbociclib; Almonertinib+Palbociclib
Sun Yat sen University Cancer Center; Sun Yat-sen University Cancer Center, Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
KRAS mutant advanced solid tumors
 
 
CTR20182414: Pharmacokinetic study of HS-10296 tablets taken by healthy subjects before and after meals

Completed
1
20
China
Ameile (aumolertinib) - Jiangsu Hansoh Pharma, EQRx
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Locally advanced or metastatic non-small cell lung cancer
 
 
ACTRN12621000848808: To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Caucasian and Ethnic Chinese Populations

Recruiting
1
30
 
EQRx, Inc, EQRx, Inc
Non Small Cell Lung Cancer
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lerociclib (G1T38) / Walvax, Pharmacosmos
LEONARDA-1, NCT05054751: GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Completed
3
275
RoW
GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant
Genor Biopharma Co., Ltd.
Locally Advanced or Metastatic Breast Cancer
12/22
03/24
ENGOT-EN17, NCT05712941: Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

Withdrawn
3
320
NA
Lerociclib, Letrozole 2.5mg, Placebo
EQRx International, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Endometrial Carcinoma
03/24
03/25
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Recruiting
3
350
RoW
GB491 combined with Letrozole, Placebo combined with Letrozole
Genor Biopharma Co., Ltd.
Breast Cancer
01/26
01/27
NCT05085002 / 2021-005238-40: A Study of Lerociclib in Participants With Advanced Breast Cancer

Terminated
2
100
Europe, US, RoW
Lerociclib + Letrozole or Fulvestrant
EQRx, Inc.
Advanced Breast Cancer
11/23
11/23
NCT02983071 / 2016-001485-29: G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Active, not recruiting
1/2
102
Europe, RoW
G1T38, lerociclib, Fulvestrant, Faslodex
G1 Therapeutics, Inc.
Carcinoma, Ductal, Breast, Breast Cancer, Breast Neoplasm
06/23
10/23
NCT05860582: A Study of [14C]GB491 in Male Healthy Subjects

Completed
1
6
RoW
[14C]GB491
Genor Biopharma Co., Ltd.
Breast Cancer, Nonsmall Cell Lung Cancer
11/22
11/22
NCT05337657: A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Recruiting
1
10
RoW
GB491+Letrozole
Genor Biopharma Co., Ltd.
Advanced Breast Cancer
12/23
02/24
vociprotafib (RMC-4630) / Revolution Medicines
2021-003254-23: Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies

Not yet recruiting
2
46
Europe
RMC-4630 - 20 mg, LUMYKRAS, RMC-4630 - 100 mg, RMC-4630, Sotorasib, Capsule, Tablet, -, Sotorasib, RMC-4630
Revolution Medicines, Inc., Revolution Medicines
Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies, Non-Small Cell Lung Cancer Subjects with KRASG12C Mutation After Failure of Prior Standard Therapies, Diseases [C] - Cancer [C04]
 
 
RMC-4630-03, NCT05054725 / 2021-003254-23: Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Completed
2
47
Europe, Canada, US, RoW
RMC-4630, SAR442720, Sotorasib, AMG 510, Lumakras
Revolution Medicines, Inc., Sanofi, Amgen
Non-Small Cell Lung Cancer
07/24
08/24
NCT04418661: Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

Terminated
1/2
65
Europe, US, RoW
Vociprotafib, SAR442720, RMC-4630, Pembrolizumab, Adagrasib
Sanofi, Revolution Medicines, Inc., Mirati Therapeutics Inc.
Metastatic Neoplasm
04/24
04/24
NCT03634982: Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Active, not recruiting
1
133
US
RMC-4630
Revolution Medicines, Inc., Sanofi
Solid Tumors
03/23
05/23
SHERPA, NCT04916236: Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers

Terminated
1
24
Europe
RMC-4630, SAR442720, LY3214996
The Netherlands Cancer Institute, Lustgarten Foundation
Pancreatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, KRAS Mutation-Related Tumors
07/24
07/24
CodeBreak101, NCT04185883 / 2020-004721-23: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Checkmark Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from CodeBreak 101 tria in combination with Vectibix in KRAS G12C-mutated CRC at ESMO 2022
Checkmark Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Sep 2022 - Sep 2022: Data from CodeBreak 101 trial in combination with panitumumab for colorectal cancer at ESMO 2022
Checkmark Presentation of data from CodeBreak 101 and CodeBreak 100 in combination with Keytruda and Tecentriq for 2L NSCLC at IASLC-WCLC 2022
More
Recruiting
1
1200
Europe, Canada, Japan, US, RoW
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Amgen, Amgen Inc, Amgen Inc.
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
06/26
12/27
Ameile (aumolertinib) / Jiangsu Hansoh Pharma
ChiCTR2000040853: A prospective, multicenter, real world study: Almonertinib mesilate tablets for EGFR Positive locally advanced or metastatic Non-Small Cell Lung Cancer

Recruiting
4
300
 
Non-intervention study
JiangSu Cancer Hospital; JiangSu Cancer Hospital, Lian Yun Gang Shi Hui Lan Public Foundation
Lung Cancer
 
 
ChiCTR2200055992: Mechanism of resistance to second-line Aumolertinib and exploring combined treatment after resistance

Not yet recruiting
4
50
 
Aumolertinib
The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University, Huilan Public Welfare Foundation
Lung cancer
 
 
ChiCTR2000035591: Multi-Center Clinical Study on the Efficacy and Safety of Almonertinib Combined with Bevacizumab and Pemetrexed in the First-Line Treatment of EGFR-Mutant Lung Adenocarcinoma Patients with Brain Metastases

Not yet recruiting
4
200
 
Almonertinib Combined with Bevacizumab and Pemetrexed
Shandong Cancer Hospital Affiliated to Shandong University; Shandong Cancer Hospital Affiliated to Shandong University, This work was partly supported by Lianyungang Huilan Public Welfare Foundation, and the rest is self-funded
Lung Adenocarcinoma
 
 
ChiCTR2100046251: Evaluate the Safety and Efficacy of Almonertinib in the Treatment of Advanced NSCLC Patients With EGFR-Sensitive Mutations Who Are Safety Intolerant After Osimertinib Treatment: a Prospective, Multi-Center, Single-Arm Clinical Trial

Recruiting
4
40
 
received 110 mg of Almonertinib orally once a day
Shanghai Chest Hospital; The Affiliated Tumor Hospital of Chongqing University, Sponsored by Jiangsu Hausen Pharmaceutical Group Co., Ltd.
Non-small-cell lung carcinoma
 
 
ChiCTR2200057150: A prospective, open, randomized, controlled, multicenter trial of postoperative adjuvant chemoradical radiotherapy followed by sequential maintenance therapy with ametinib versus postoperative adjuvant chemoradical radiotherapy in patients with stage N2-III NSCLC with EGFR mutations

Not yet recruiting
4
102
 
Aumolertinib after adjuvant chemotherapy/radiotherapy ;Adjuvant chemotherapy/radiotherapy
The People's Hospital of Guizhou Province; The People's Hospital of Guizhou Province, Huilan charity-Hansoh pharma
non-small cell lung cancer (NSCLC)
 
 
SELECT-2, NCT04401059: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study

Recruiting
4
744
RoW
Elemene plus first or third generation EGFR-TKIs, H10960114, H20010338, First or third generation EGFR-TKIs, Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc.
Tian Xie, LinkDoc Technology (Beijing) Co. Ltd.
Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma
09/25
03/26
ChiCTR2100042856: Clinical study of ametinib as neoadjuvant therapy in EGFR positive patients with stage IIB to IIIA non-small cell lung cancer

Recruiting
4
30
 
almonertinib
Huadong Hospital; Huadong Hospital, LIAN YUN GANG SHI HUI LAN PUBLIC FOUNDATION
Lung Cancer
 
 
ChiCTR2200063184: A multicenter, open-label, single-arm clinical study of Aumolertinib mesylate as postoperative adjuvant treatment for patients with EGFRm positive stage IB and pure solid stage IA2-3 invasive non-small cell lung cancer

Not yet recruiting
4
130
 
Aumolertinib as postoperative adjuvant therapy
The First Affiliated Hospital of Sun Yat-sen University ; The First Affiliated Hospital of Sun Yat-sen University, Huilan charity-Hansoh pharma
non-small cell lung cancer (NSCLC)
 
 
ChiCTR2200062887: A multicenter, open-label, single-arm clinical study of Aumolertinib mesylate as postoperative adjuvant treatment for patients with EGFRm positive stage IB and pure solid stage IA2-3 invasive Non-Small Cell Lung Cancer

Not yet recruiting
4
130
 
Aumolertinib as postoperative adjuvant therapy
The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University, Huilan charity-Hansoh pharma
Lung Cancer
 
 
CTR20201857: Phase III clinical study of ametinib mesylate or placebo combined with chemotherapy as perioperative treatment for non-small cell lung cancer

Not yet recruiting
3
350
China
Ameile (aumolertinib) - Jiangsu Hansoh Pharma, EQRx, Pemfexy (pemetrexed) - Eagle Pharma, cisplatin - Generic mfg., carboplatin - Generic mfg.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd./Shanghai Hansoh Biomedical Technology Co., Ltd.
Non-small cell lung cancer;Oncology
 
 
AENEAS, NCT03849768: A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Active, not recruiting
3
429
RoW
HS-10296, Investigational Product, Gefitinib, Comparator Product
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
01/21
06/23
ACROSS1, NCT04500704: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC

Not yet recruiting
3
166
RoW
Almonertinib, Ameile, Almonertinib plus carboplatin and pemetrexed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
12/21
10/23
ACROSS2, NCT04500717: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation

Not yet recruiting
3
460
RoW
Almonertinib, Aleime, Almonertinib plus carboplatin and pemetrexed
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
10/22
10/23
APPROACH, NCT04841811: MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.

Recruiting
3
192
RoW
Almonertinib, ctDNA dynamic monitoring guided the Almonertinib treatment
Guangdong Association of Clinical Trials, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer
12/24
12/26
ACROSS 1, ChiCTR2000032354: Almonertinib Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Patients With EGFR Mutation Positive With Concomitant Non-EGFR Driver Gene Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Randomized, Control Phase III Study

Recruiting
3
166
 
Almonertinib 110mg PO once daily ;110mg PO once daily and 500 milligrams per square meter (mg/m2) Pemetrexed and AUC=5 Carboplatin taken intravenously (IV) once every 3 weeks concurrently with Almonertinib taken orally QD.
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, self-financing and partial sponsorship of Jiangsu Haosen Pharmaceutical Group Co., Ltd
NSCLC
 
 
ACROSS 2, ChiCTR2000032319: Almonertinib Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Patients With EGFR Mutation Positive With Concomitant Tumor Suppressor Gene Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Randomized, Control Phase III Study

Recruiting
3
460
 
Almonertinib, 110mg, P.O., once daily and 500 milligrams per square meter (mg/m2) Pemetrexed and AUC=5 Carboplatin taken intravenously (IV) once every 3 weeks concurrently with Almonertinib taken orally QD. ;Almonertinib, 110mg, P.O., once daily
Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, self-financing and partial sponsorship of Jiangsu Haosen Pharmaceutical Group Co., Ltd.
NSCLC
 
 
TREBLE, NCT05493501: Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Terminated
3
8
US
Aumolertinib monotherapy, EQ143, HS-10296, Osimertinib monotherapy, Tagrisso, Pemetrexed, Alimta, Cisplatin, Carboplatin, Paclitaxel, Taxol, Nab paclitaxel, Abraxane, Albumin-bound paclitaxel, Gemcitabine, Gemzar
EQRx International, Inc.
NSCLC
08/23
08/23
NCT04951648: A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Not yet recruiting
3
220
RoW
Almonertinib, HS-10296, chemotherapy
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
10/23
09/24
AENEAS2, NCT04923906: Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Active, not recruiting
3
624
RoW
Aumolertinib, HS-10296, Placebo Aumolertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
06/24
01/26
ATTACK, NCT04870190: Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Not yet recruiting
3
232
NA
Almonertinib, HS-10296, Osimertinib, Teresa, AZD9291
Shanghai Chest Hospital
NSCLC
06/24
06/24
ChiCTR2100047453: Efficacy and safety of almonertinib combined with apatinib versus almonertinib as a single agent in the first-line treatment of advanced NSCLC with EGFR-sensitive mutations: a multicenter, randomized, open, controlled phase iii clinical study

Recruiting
3
300
 
Almonertinib 110mg PO once daily plus apatinib 250mg PO once daily ;Almonertinib 110mg PO once daily
Chinese PLA General Hospital; Chinese PLA General Hospital, Self-raised and sponsored by Jiangsu Haosen Pharmaceutical Group Co., Ltd., and sponsored by Jiangsu Hengrui Pharmaceutical Co., Ltd.
NSCLC
 
 
POLESTAR, NCT04951635: A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Recruiting
3
150
RoW
Almonertinib, HS-10296, Placebo Almonertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
07/24
01/27
ADVANCE, ChiCTR2000040590: Almonertinib Plus Radiotherapy compared with Concurrent RadioChemotherapy in the treatment of unresectable EGFR-mutated stage III Non-Small Cell Lung Cancer: a Multicenter, Open-Label, Randomized, Control Phase III Study

Not yet recruiting
3
254
 
Almonertinib 110mg PO once daily ;Cisplatin（75mg/m2），and 500 milligrams per square meter (mg/m2) Pemetrexed
Cancer Hospital Chinese Acadmey of Medical Sciences, Shenzhen Center; Shanghai chest hospital, self-financing and partial sponsorship of Jiangsu Haosen Pharmaceutical Group Co., Ltd
NSCLC
 
 
HS-10241-301, NCT06110663: A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Not yet recruiting
3
314
NA
HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
12/24
02/25
ARTS, NCT04687241: Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations

Active, not recruiting
3
192
RoW
Almonertinib, HS-10296, Placebo Almonertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
07/24
01/29
APEX, NCT04762459: Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection

Enrolling by invitation
3
606
RoW
Almonertinib, Pemetrexed, Cisplatin
Chinese Academy of Medical Sciences, Jiangsu Hansoh Pharmaceutical Co., Ltd., GeneCast Biotechnology Co., Ltd.
Non-small Cell Lung Carcinoma
05/26
05/29
NCT06043973: Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Recruiting
3
98
RoW
almonertinib, Anlotinib
Qianfoshan Hospital
Advanced Non-small Cell Lung Cancer
09/26
06/27
NCT05800223: Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Recruiting
3
300
RoW
Almonertinib, SBRT
Shanghai Cancer Hospital, China
Non-small Cell Lung Cancer Metastatic
12/27
12/28
NCT05768490: Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Recruiting
3
232
RoW
brain radiotherapy, Almonertinib
Sun Yat-sen University
Brain Metastases, Radiotherapy, EGFR Activating Mutation
12/28
12/29
HS-20117 301, NCT06417008: A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Not yet recruiting
2/3
1080
NA
HS-20117, PM1080, Aumolertinib, Almonertinib Mesilate Tablets, HS-10296, Almonertinib
Hansoh BioMedical R&D Company
Non-Squamous Non-Small Cell Lung Cancer
06/26
06/30
NCT05994339: Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Not yet recruiting
2/3
40
NA
Almonertinib, Intensity-Modulated Radiation Therapy(IMRT)
Laibin People's Hospital
Lung Cancer Stage III
08/25
12/25
NCT04646824: Almonertinib With Chemotherapy in mEGFR NSCLC

Active, not recruiting
2
10
RoW
Almonertinib Pemetrexed/Cisplatin
Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer Metastatic
11/20
11/22
NCT04671303: To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer

Completed
2
36
RoW
Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer
06/23
07/23
NCT04636593: A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Recruiting
2
43
RoW
Almonertinib, Thoracic Radiotherapy
First People's Hospital of Hangzhou, Hangzhou Cancer Hospital
Non Small Cell Lung Cancer, Stage III NSCLC, EGFR Activating Mutation
12/21
12/22
APPEAL, NCT04592666: Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer

Not yet recruiting
2
226
RoW
Almonertinib, Pemetrexed, Carboplatin
Fudan University
Lung Cancer, Non-small Cell, EGFR T790M, EGFR Gene Mutation
12/21
06/22
GASTO 1063, NCT04978753: the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

Recruiting
2
54
RoW
Anlotinib, almonertinib
Li-kun Chen
Non-small Cell Lung Cancer, Brain Metastases
05/22
12/23
NCT04952168: Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Recruiting
2
26
RoW
Almonertinib
Yuan Chen
NSCLC, Stage III
06/22
06/23
NCT04423185: PLATFORM Study of Precision Medicine for Rare Tumors

Recruiting
2
770
RoW
Almonertinib 110 MG, HS-10296, AMEILE, Dacomitinib 45 MG, Vizimpro, Alectinib 150 MG, Alecensa, Crizotinib 250 MG, Xalkori, Pyrotinib 160/80 MG, SHR-1258, Imatinib 400 MG, Gleevec, Niraparib 200/300 MG, Niraparix, Palbociclib 125mg, Ibrance, Vemurafenib 240 MG, Zelboraf, Sintilimab 100MG, Tyvyt, Atezolizumab 1680 MG, TECENTRIQ
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rare Tumor
07/26
07/28
NCT04643847: A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases

Not yet recruiting
2
47
RoW
Almonertinib, HS-10296
First People's Hospital of Hangzhou
EGFR Positive Non-small Cell Lung Cancer, Brain Metastases
11/22
11/23
NCT03904823: A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

Recruiting
2
58
RoW
famitinib po, HS-10296 po
Jiangsu HengRui Medicine Co., Ltd.
EGFR-mutant Non-Small Cell Lung Cancer
12/22
12/22
PIKACHU, NCT04322890: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Recruiting
2
6000
RoW
Osimertinib, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc., Alectinib 150 MG, Lorlatinib, Alectinib, Brigatinib, Ceritinib etc., Crizotinib 250 MG, Entrectinib, Savolitinib, Crizotinib., Crizotinib, Chemotherapy, Pemetrexed, Cisplatin, Pralsetinib etc.
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation
12/26
12/27
LungMate-007, NCT04685070: Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer

Active, not recruiting
2
56
RoW
HS-10296 (Almonertinib)
Shanghai Pulmonary Hospital, Shanghai, China
Non-small Cell Lung Cancer Stage III
12/22
12/27
ChiCTR2200066768: Clinical observation of Aumolertinib in the treatment of residual ground glass nodules in patients with Ⅰ stage EGFR mutation positive after resection of lung cancer

Not yet recruiting
2
40
 
Aumolertinib
Tianjin medical university cancer institute&hospital; Tianjin medical university cancer institute&hospital, None
Lung Cancer
 
 
ANSWER, NCT04455594: Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC

Not yet recruiting
2
168
RoW
Almonertinib, HS-10296, Erlotinib, Cisplatin, Carboplatin, Pemetrexed
The First Affiliated Hospital of Guangzhou Medical University
Non-Small Cell Lung Cancer Stage IIIA
01/23
10/25
MWA, NCT04755738: Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer

Not yet recruiting
2
234
RoW
Almonertinib plus microwave ablation, Microwave ablation
Qianfoshan Hospital, Shandong Provincial Hospital
Advanced Non Small Cell Lung Cancer
03/23
03/25
AUTUMN, NCT04553887: Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial

Not yet recruiting
2
53
RoW
Almonertinib
Tianjin Medical University Cancer Institute and Hospital
Non Small Cell Lung Cancer
05/23
05/23
ChiCTR2100049904: Clinical observation of continuous treatment with almonertinib after treatment with osimertinib in EGFR mutation positive advanced NSCLC patients with drug resistance

Not yet recruiting
2
30
 
Almonertinib 110 mg orally,once a day
Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University; Jinshan Hospital of The First Affiliated Hospital of Chongqing Medical University, Huilan charity-Hansoh pharma
Lung Cancer
 
 
APPEAR, NCT04785729: Almonertinib Combined With Pyrotinib in the Treatment of Advanced NSCLC Patients With HER-2 Amplification/Mutation After EGFR-TKI Resistance

Recruiting
2
36
RoW
Almonertinib combine with Pyrrolitinib
Sun Yat-sen University
Safety
12/23
12/23
NCT04519983: Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

Recruiting
2
40
RoW
Aumolertinib Oral Tablet, Stereotactic Radiation Therapy
Shanghai Cancer Hospital, China
Lung Cancer Stage IV
12/23
12/23
NCT05754736: Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.

Recruiting
2
50
RoW
Ametinib combined with bevacizumab, Third-generation TKI combined with antivascular targeting drug
The Second Affiliated Hospital of Shandong First Medical University
Non-small Cell Lung Cancer
12/23
12/25
NCT05662813: Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy

Recruiting
2
55
RoW
Almonertinib, HS-10296
West China Hospital
Non-small Cell Lung Cancer
12/23
06/25
ChiCTR2000039310: Platform Study of Genotyping Guided Precision Medicine for Rare Tumors in China

Recruiting
2
208
 
Almonertinib, 110mg, qd ;Dacomitinib, 450mg, qd ;Alectinib, 600mg, bid ;Crizotinib, 250mg, bid ;Zelboraf, 960mg, bid ;Niraparib,200-300mg,qd ;Pyrotinib, 400mg, qd ;Imatinib, 400mg, bid ;Palbociclib, 125mg,*21d, q28d ;Sintilimab, 200mg, q21d ;Atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d
National Cancer Center/National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital of Chinese Academy of Medical Sciences, self-raised
Rare Tumors
 
 
NCT04785742: Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR

Enrolling by invitation
2
40
RoW
Almonertinib
Sun Yat-sen University
Safety of Almonertinib
12/23
12/23
ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma

Recruiting
2
13
RoW
Almonertinib, Investigational Product
Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Pulmonary Adenosquamous Carcinoma
12/23
06/25
ACTIVE, NCT04882345: Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Not yet recruiting
2
40
NA
Almonertinib, HS-10296
Shanghai Chest Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer, EGFR Gene Mutation
01/24
01/24
NCT06185400: RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Not yet recruiting
2
108
NA
Disitamab Vedotin, RC48, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib), pyrotinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, ERBB2 Gene Duplication, Disitamab Vedotin
07/25
12/26
NCT04905550: Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

Recruiting
2
50
RoW
Almonertinib, The third generation of EGFR - TKI, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
Chongqing University Cancer Hospital
Non-Small Cell Lung Cancer (NSCLC)
03/24
08/24
ACHIEVE, NCT04808752: Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

Active, not recruiting
2
63
RoW
Almonertinib, Investigational Product
Zhejiang Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer
06/24
07/24
NEOVADE, NCT06300424: Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Recruiting
2
32
RoW
almonertinib, Carboplatin, Nab paclitaxel
Guangdong Provincial People's Hospital
Non Small Cell Lung Cancer, EGFR Gene Mutation
03/26
09/27
APPOINT, NCT04922138: Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns

Recruiting
2
104
RoW
Aumolertinib, HS-10296
Baohui Han, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer
04/24
10/25
NCT06463171: Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer

Not yet recruiting
2
60
RoW
Almonertinib, Lastet
Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Zhongshan Hospital, The First Affiliated Hospital of Xiamen University
Lung Cancer Non-small Cell Stage IV
06/26
06/26
NCT06452433: Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Not yet recruiting
2
91
NA
gumarontinib, SCC244, third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib), third-generation EGFR-TKI
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer
12/27
02/28
AERESA, NCT06227897: Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC ().

Withdrawn
2
85
RoW
Aumolertinib, almonertinib, HS-10296
Sun Yat-sen University
Lung Cancer
04/26
04/29
ANSWER, ChiCTR2000033677: Almonertinib vs. Erlotinib / Chemotherapy for Neo-Adjuvant Treatment of Stage IIIA-N2 EGFR-Mutated NSCLC: a Multicenter, Open-Label, Phase II Randomized Controlled Trial

Not yet recruiting
2
168
 
Almonertinib 110mg PO once daily ;Investigator-choice therapy: Erlotinib 150mg PO once daily or 500 milligrams per square meter (mg/m2) Pemetrexed and AUC=5 Carboplatin/75 milligrams per square meter (mg/m2) cisplatin taken intravenously (IV) once every 3 weeks
The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University, Self-financing and partial sponsorship of Jiangsu Haosen Pharmaceutical Group Co., Ltd.
NSCLC
 
 
ANOTHER, NCT06752408: Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

Not yet recruiting
2
316
RoW
Aumolertinib, Osimertinib
Peking Union Medical College Hospital, Peking University People's Hospital, China-Japan Friendship Hospital
Non Small Cell Lung Cancer
01/27
01/28
NCT05810350: Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles

Recruiting
2
40
RoW
Aumonertinib 165mg orally once daily and intrathecal chemotherapy with pemetrexed
Three Gorges Hospital of Chongqing University
Non-small Cell Lung Cancer
12/24
12/24
NCT05778149: Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Not yet recruiting
2
47
NA
Aumolertinib,Anlotinib
Tianjin Medical University Cancer Institute and Hospital
Aumolertinib, Anlotinib, TP53, NSCLC, EGFR Activating Mutation
03/25
03/27
NCT06951464: Phase II Study of BL-B01D1 and Almonertinib for EGFR+ Stage II-IIIB NSCLC

Not yet recruiting
2
40
NA
BL-B01D1, Almonertinib
Sichuan University
Non-Small Cell Lung Cancer
05/27
03/29
NCT05534113: Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Not yet recruiting
2
38
NA
Almonertinib Envafolimab
The First Affiliated Hospital with Nanjing Medical University
Non-small Cell Lung Cancer
06/25
06/25
NCT05946460: Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.

Recruiting
2
22
RoW
Aumolertinib
The First Affiliated Hospital of Guangzhou Medical University
Lung Cancer
07/25
07/25
ChiCTR2300075120: Efficacy and Safety of Ametinib Combined With Bevacizumab in First-line Treatment of Non-oligometastatic Advanced NSCLC With EGFR-mutations.

Recruiting
2
100
 
Almonertinib plus bevacizumab
The Second Affiliated Hospital of Shandong First Medical University; The Second Affiliated Hospital of Shandong First Medical University, Self-funded
Lung cancer
 
 
ChiCTR2400083981: Phase II Clinical Study of Almonertinib in Combination with LASTET in the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer with EGFR Mutations

Not yet recruiting
2
60
 
Almonertinib in Combination with LASTET
shanghai pulmonary hospital; shanghai pulmonary hospital, Shanghai Pulmonary Hospital
Non-Small Cell Lung Cancer
 
 
ChiCTR2500095661: A Multicenter, Single-Arm, Phase II Study of High-Dose Almonertinib as First-Line Treatment for Patients with EGFR Exon 21 L858R-Mutated Advanced Lung Adenocarcinoma (LUAD)

Recruiting
2
122
 
Almonertinib 165mg, oral, once daily (QD)
The Affiliated Panyu Central Hospital of Guangzhou Medical University; The Affiliated Panyu Central Hospital of Guangzhou Medical University, Self-funded
EGFR Exon 21 L858R-Mutated Advanced Lung Adenocarcinoma
 
 
ChiCTR2300078018: Efficacy and safety of Almonertinib as postoperative adjuvant therapy for completely resected stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations

Not yet recruiting
2
50
 
Targeted Therapy Intervention
Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, HANSOH PHARMACY
completely resected IB-IIIA non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations (except for 20ins)
 
 
PURPOSE Trial, ChiCTR2100053021: Precise neoadjuvant therapy for locally advanced non-small cell lung cancer: a prospective, observational, umbrella trial

Not yet recruiting
2
156
 
Almonertinib ;Furmonertinib ;Osimertinib ;Ensartinib/Savolitinib/Pralsetinib/Pyrotinib ;Camrelizumab+chemotherapy ;Chemotherapy
Shanghai Chest Hospital; Shanghai Chest Hospital, Self-raised
Locally advanced non-small cell lung cancer
 
 
ChiCTR2500102344: A Phase II Study to Evaluate the Safety and Efficacy of Neoadjuvant Therapy with BL-B01D1 in Combination with Almonertinib Followed by Adjuvant Almonertinib in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIB Resectable Non-Small Cell Lung Cancer

Not yet recruiting
2
40
 
BL-B01D1 plus Almonertinib
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Self-selected topic (self-sponsored)
Stage II-IIIb non-small cell lung cancer with sensitive EGFR mutations
 
 
SHR-A2009-201, CTR20233099: An open-label, multicenter phase IB/II clinical study of the safety, tolerability and efficacy of SHR-A2009 for injection in combination with anti-tumor therapy in patients with advanced solid tumors

Recruiting
1b/2
270
China
SHR-A2009 - Jiangsu Hengrui Pharma, adebrelimab (SHR-1316) - Jiangsu Hengrui Pharma, Ameile (aumolertinib) - Jiangsu Hansoh Pharma
Shengdia Biopharmaceutical Co., Ltd
Advanced solid tumors
 
 
APOLLO, NCT02981108: A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

Active, not recruiting
1/2
364
US
HS-10296
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Nonsmall Cell Lung Cancer
01/19
03/23
ChiCTR2100049102: Aumolertinib combined with bevacizumab in the first-line treatment of advanced NSCLC patients with EGFR-sensitive mutations and malignant pleural effusion and/or malignant pericardial effusion: a phase I/II clinical study

Not yet recruiting
1/2
36
 
Aumolertinib 110 mg orally, once a day; bevacizumab 15 mg/kg intravenous drip (on the first day of each cycle), every 21 days as a cycle.
The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, Huilan Charity-Hansoh pharma
non-small cell lung cancer
 
 
NCT06474455: A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
156
RoW
SHR-9839 ；SHR-A2009, SHR-9839 ； SHR-A1921, SHR-9839 ； pemetrexed ；carboplatin, SHR-9839 ； Almonertinib
Shanghai Hengrui Pharmaceutical Co., Ltd.
Advanced Solid Tumors
06/26
06/27
ChiCTR2200060886: A phase Ⅰ/Ⅱ study of Almonertinib with Bevacizumab in the first-line treatment of EGFR-mutant non-squamous non-small cell lung cancer patients with brain metastases

Not yet recruiting
1/2
94
 
NA
The Second Affiliated Hospital of Chongqing Medical University ; The Second Affiliated Hospital of Chongqing Medical University, self-financing
lung cancer
 
 
APEAK, NCT06947811: A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

Recruiting
1/2
71
RoW
Almonertinib, Palbociclib
Sun Yat-sen University
EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
03/27
03/27
SHR-A2009-201, NCT06092268: A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
270
NA
SHR-A2009 for injection ； Almonertinib Mesilate Tablets, SHR-A2009 for injection；Adebrelimab Injection
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
12/25
12/25
SHR-1701-215, NCT05503888: Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Not yet recruiting
1/2
160
NA
Almonertinib combined with SHR-1701, Almonertinib
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Relapsed or Advanced Non-small Cell Lung Cancer
07/27
07/27
ChiCTR2500101627: A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations (APEAK)

Not yet recruiting
1/2
72
 
Almonertinib+Palbociclib; Almonertinib+Palbociclib
Sun Yat sen University Cancer Center; Sun Yat-sen University Cancer Center, Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
KRAS mutant advanced solid tumors
 
 
CTR20182414: Pharmacokinetic study of HS-10296 tablets taken by healthy subjects before and after meals

Completed
1
20
China
Ameile (aumolertinib) - Jiangsu Hansoh Pharma, EQRx
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Locally advanced or metastatic non-small cell lung cancer
 
 
ACTRN12621000848808: To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Caucasian and Ethnic Chinese Populations

Recruiting
1
30
 
EQRx, Inc, EQRx, Inc
Non Small Cell Lung Cancer
 
 
 

Download Options